Using podocalyxin-expressing A-172 glioblastoma cells as an immunogen, we generated a novel panel of anti-human podocalyxin mAbs that exhibit preferential binding to podocalyxin expressed on human tumor cells. The gene discussed is PODXL; the disease is glioblastoma.